The Department of Health and Human Services issued a Health Alert Network Update notifying healthcare providers and facilities that COVID-19 monoclonal antibody (mAb) therapy has a new indication for post-exposure prophylaxis via emergency use authorization. As of September 13, the US Government began allocating mAb therapy; infusion sites will no longer order mAb therapy directly from distributors.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.